{
  "docId": "019de071-1bdd-70bb-9c61-980d0c38b663",
  "docSlug": "a4792f18c57ea3f4ba27e696a63520de",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4148858,
  "pageNumber": 21,
  "pageCount": 40,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "The slide uses a three-column layout to compare different drug assets in the pipeline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1bdd-70bb-9c61-980d0c38b663/21",
  "deckHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663",
  "deckJsonHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663.json",
  "deckAnchorHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Best change in sum of diameters, %",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3030f163-6d66-4982-8eca-aed638242292",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Capivasertib (AZD5363): oral AKT inhibitor. Breast Phase III trials underway: CAPItello-291, CAPItello-292. TNBC Phase III trial underway: CAPItello-290.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "590ea19a-1361-4177-82b5-4a94d6a67cb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.35,
        "y": 0.58
      },
      "kind": "metric",
      "text": "42.3% clinical benefit rate",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2dd1de79-1b60-4a13-be4b-ddf0b0fe3c74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "metric",
      "text": "16.3% overall response rate",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3db67d11-4f47-4437-a698-df94498877bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Source: abstract 1005, ASCO 2019; abstract 1007, ASCO 2018. N.B. Faslodex provided ~5-10% ORR in similar setting. Source: abstract 1024, ASCO 2020.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d89fddd-7c8f-4379-9dab-070f24b0439d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "table",
      "text": "Objective response rate 9 (43%), CR/PR (confirmed) 5 (24%), CR/PR (pending) 4 (19%), Disease control rate 20 (95%), Progressive disease 1 (5%)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b86b537f-d566-4ee1-ad6e-17d54b7c43a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "title",
      "text": "Phase III trials underway and planned",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8872f04f-388f-4575-903b-67a0adfb69b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "title",
      "text": "Breast cancer: competitive late-stage breast cancer pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1be5bc9-e967-40d9-ac08-497435775d8b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "9bb24be0-c8c7-49aa-a526-e9fcc4794b51",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document concludes with a call to action and next steps for investors.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 21,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cde01b8e-53ce-45e4-b3c4-d519c08ca374",
      "evidence": "The document implies that not investing in oncology would result in missed opportunities for growth and patient benefit.",
      "position": 1,
      "objective": "What are the consequences of not investing in oncology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}